Cell Rep:防治帕金森病的关键可能在肠道

2016-10-08 佚名 生物谷

一项最新研究表明,肠道可能在预防帕金森病发生方面起到重要作用,原因可能在于小肠免疫细胞对线粒体的"监控"。 爱荷华大学的研究人员发现肠道可能是预防帕金森病的关键,位于小肠的免疫细胞启动免疫应答能够保护神经元对抗与帕金森病有关的损伤。"我们认为肠道正在保护神经元。"Veena Prahlad教授这样说道。相关研究结果发表在国际学术期刊Cell Reports上。 科学家们


一项最新研究表明,肠道可能在预防帕金森病发生方面起到重要作用,原因可能在于小肠免疫细胞对线粒体的"监控"。

爱荷华大学的研究人员发现肠道可能是预防帕金森病的关键,位于小肠的免疫细胞启动免疫应答能够保护神经元对抗与帕金森病有关的损伤。"我们认为肠道正在保护神经元。"Veena Prahlad教授这样说道。相关研究结果发表在国际学术期刊Cell Reports上。

科学家们之前曾经发现帕金森病与线粒体缺陷之间存在关联,但是线粒体缺陷如何影响神经元一直成谜。有些学者认为损伤的线粒体会造成神经元出现能量饥饿;另外一些人认为损伤的线粒体会产生一些可对神经元造成损伤的分子。无论答案是什么,许多研究也提示损伤的线粒体也与其他一些神经紊乱存在关联,比如ALS和阿尔茨海默病,因此研究人员想要深入了解其中的原因。

研究人员将蛔虫暴露于一种叫做鱼藤酮的毒性物质,这种毒性物质能够杀死与帕金森病有关的神经元。正如预期,鱼藤酮损伤了蛔虫神经元的线粒体,令研究人员感到意外的是,损伤的线粒体并没有杀死所有合成多巴胺的神经元;除此之外,他们通过大量实验发现平均只有7%的蛔虫(大约3000只蛔虫中有210只)在暴露于鱼藤酮的实验中会失去合成多巴胺的神经元。

研究人员想就其中的一些保护性机制进行深入探讨。

他们发现鱼藤酮激活了蛔虫的免疫防御,使其抛弃了许多损伤的线粒体,阻止了一系列可能导致合成多巴胺的神经元出现损失的事件。这其中非常重要的是,研究人员发现免疫应答起源于小肠而非神经系统。

研究人员计划未来进行更多实验,现阶段他们也得到一些非常有趣的假设。其中一种假设就是小肠免疫细胞能够持续监测线粒体是否出现损伤缺陷。免疫细胞"不信任"线粒体的原因可能在于,一种比较流行的理论认为很早以前线粒体作为一种细菌独立存在,后来与细胞融合在一起。如果这一理论是正确的,小肠免疫细胞可能对于线粒体功能的变化特别敏感。不过这一理论仍需要更多实验来验证。

原始出处:

Madhusudana Rao Chikka, Charumathi Anbalagan, Katherine Dvorak, Kyle Dombeck, Veena Prahlad.The Mitochondria-Regulated Immune Pathway Activated in the C. elegans Intestine Is Neuroprotective.Cell Rep DOI: 10.1016/j.celrep.2016.07.077

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1869578, encodeId=29c018695e835, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Feb 27 02:05:00 CST 2017, time=2017-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959837, encodeId=d112195983e85, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Dec 23 15:05:00 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148290, encodeId=6e45148290b2, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387c1637569, createdName=liusanxin, createdTime=Fri Oct 14 22:18:46 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=142287, encodeId=f96414228e21, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Sun Oct 09 00:27:44 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=142286, encodeId=bed214228659, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Sun Oct 09 00:27:38 CST 2016, time=2016-10-09, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1869578, encodeId=29c018695e835, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Feb 27 02:05:00 CST 2017, time=2017-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959837, encodeId=d112195983e85, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Dec 23 15:05:00 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148290, encodeId=6e45148290b2, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387c1637569, createdName=liusanxin, createdTime=Fri Oct 14 22:18:46 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=142287, encodeId=f96414228e21, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Sun Oct 09 00:27:44 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=142286, encodeId=bed214228659, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Sun Oct 09 00:27:38 CST 2016, time=2016-10-09, status=1, ipAttribution=)]
    2016-12-23 维他命
  3. [GetPortalCommentsPageByObjectIdResponse(id=1869578, encodeId=29c018695e835, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Feb 27 02:05:00 CST 2017, time=2017-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959837, encodeId=d112195983e85, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Dec 23 15:05:00 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148290, encodeId=6e45148290b2, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387c1637569, createdName=liusanxin, createdTime=Fri Oct 14 22:18:46 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=142287, encodeId=f96414228e21, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Sun Oct 09 00:27:44 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=142286, encodeId=bed214228659, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Sun Oct 09 00:27:38 CST 2016, time=2016-10-09, status=1, ipAttribution=)]
    2016-10-14 liusanxin

    继续学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1869578, encodeId=29c018695e835, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Feb 27 02:05:00 CST 2017, time=2017-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959837, encodeId=d112195983e85, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Dec 23 15:05:00 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148290, encodeId=6e45148290b2, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387c1637569, createdName=liusanxin, createdTime=Fri Oct 14 22:18:46 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=142287, encodeId=f96414228e21, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Sun Oct 09 00:27:44 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=142286, encodeId=bed214228659, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Sun Oct 09 00:27:38 CST 2016, time=2016-10-09, status=1, ipAttribution=)]
    2016-10-09 知难而进

    继续关注!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1869578, encodeId=29c018695e835, content=<a href='/topic/show?id=fd764459a8' target=_blank style='color:#2F92EE;'>#Cell#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4459, encryptionId=fd764459a8, topicName=Cell)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=524d95, createdName=zhaozhouchifen, createdTime=Mon Feb 27 02:05:00 CST 2017, time=2017-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1959837, encodeId=d112195983e85, content=<a href='/topic/show?id=dbe6445416' target=_blank style='color:#2F92EE;'>#CEL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4454, encryptionId=dbe6445416, topicName=CEL)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c3ff68, createdName=维他命, createdTime=Fri Dec 23 15:05:00 CST 2016, time=2016-12-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=148290, encodeId=6e45148290b2, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387c1637569, createdName=liusanxin, createdTime=Fri Oct 14 22:18:46 CST 2016, time=2016-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=142287, encodeId=f96414228e21, content=继续关注!, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Sun Oct 09 00:27:44 CST 2016, time=2016-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=142286, encodeId=bed214228659, content=谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160811/IMG57AC91915ACA64463.jpg, createdBy=9c351934462, createdName=知难而进, createdTime=Sun Oct 09 00:27:38 CST 2016, time=2016-10-09, status=1, ipAttribution=)]
    2016-10-09 知难而进

    谢谢分享!

    0